World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
38620
World Ranking
15871
National Ranking
79

Raimund Jakesz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Raimund Jakesz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 443 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Raimund Jakesz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Raimund Jakesz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Raimund Jakesz is affiliated with the Medical University of Vienna in Austria, contributing to research primarily in the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Their work spans multiple important subfields including Cancer Research, Genetics, Oncology, Pathology and Forensic Medicine, and Pulmonary and Respiratory Medicine.

The scientist's research mainly focuses on topics related to breast cancer, with an emphasis on Breast Cancer Treatment Studies, Estrogen and related hormone effects, Breast Lesions and Carcinomas, Advanced Breast Cancer Therapies, and Bone health and treatments. Additional work involves Cancer Cells and Metastasis as well as Bone Metabolism and Diseases.

Jakesz has been involved in several scientific publications, appearing repeatedly in key medical journals. Frequent publication venues include the European Journal of Cancer and Breast Cancer Research and Treatment, with individual contributions also published in the New England Journal of Medicine, NEJM Evidence, and the British Journal of Cancer.

Several recent papers co-authored or involving their collaboration include:

  • Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer, 2021, New England Journal of Medicine
  • Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34), 2020, European Journal of Cancer
  • Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial, 2020, European Journal of Cancer
  • Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer, 2022, NEJM Evidence
  • Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34, 2021, British Journal of Cancer

Throughout their career, Raimund Jakesz has collaborated frequently with several co-authors, including Michael Gnant, Richard Greil, Florian Fitzal, Marija Balić, and Christian F. Singer. These partnerships highlight an active engagement in multidisciplinary cancer research teams.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

    Michael Gnant;Brigitte Mlineritsch;Walter Schippinger;Gero Luschin-Ebengreuth

  • Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

    Raimund Jakesz;Walter Jonat;Michael Gnant;Martina Mittlboeck

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

    Martin Filipits;Margaretha Rudas;Raimund Jakesz;Peter Dubsky

  • Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

    Michael Gnant;Brigitte Mlineritsch;Herbert Stoeger;Gero Luschin-Ebengreuth

  • Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial

    Michael Gnant;Georg Pfeiler;Peter C Dubsky;Michael Hubalek

  • Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer

    Monika Schindl;Sebastian F. Schoppmann;Hellmut Samonigg;Hubert Hausmaninger

  • Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

    J Cuzick;L Ambroisine;N Davidson;R Jakesz

  • Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

    Michael Gnant;Brigitte Mlineritsch;Gero Luschin-Ebengreuth;Franz Kainberger

  • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

    M. Gnant;M. Filipits;R. Greil;H. Stoeger

  • Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

    Michael F.X. Gnant;Brigitte Mlineritsch;Gero Luschin-Ebengreuth;Stephan Grampp

  • TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients

    Daniela Kandioler-Eckersberger;Carmen Ludwig;Margarethe Rudas;Sonja Kappel

  • The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

    P Dubsky;J C Brase;R Jakesz;M Rudas

  • Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5

    Raimund Jakesz;Hubert Hausmaninger;Ernst Kubista;Michael Gnant

  • Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer

    Sebastian F. Schoppmann;Guenther Bayer;Klaus Aumayr;Susanne Taucher

  • Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a

    Raimund Jakesz;Richard Greil;Michael Gnant;Marianne Schmid

  • Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

    M. Gnant;B. Mlineritsch;H. Stoeger;G. Luschin-Ebengreuth

  • Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

    Walter Jonat;Michael Gnant;Francesco Boccardo;Manfred Kaufmann

Frequent Co-Authors

Michael Gnant
Michael Gnant Medical University of Vienna
Richard Greil
Richard Greil Paracelsus Medical University
Christian F. Singer
Christian F. Singer Medical University of Vienna
Christoph C. Zielinski
Christoph C. Zielinski Medical University of Vienna
Christian Marth
Christian Marth Innsbruck Medical University
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
John Crown
John Crown Dublin City University
Christoph Thomssen
Christoph Thomssen University of Göttingen
Jonas Bergh
Jonas Bergh Karolinska Institute
Marc Buyse
Marc Buyse Hasselt University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their career options in the medical and healthcare field, a range of related online degrees can provide additional pathways. Many choose to pursue advanced education in management, nursing, pharmacy, or health information to open up new roles or leadership positions.

If you are drawn to the administrative side of healthcare, consider exploring the cheapest online mha programs. These programs offer affordable opportunities to develop expertise in healthcare administration while maintaining flexibility.

Registered nurses looking to advance into leadership, education, or specialized nursing roles might benefit from msn to dnp programs online. Doctor of Nursing Practice degrees can help nurses move into higher clinical or executive positions.

For those interested in the pharmaceutical side of medicine, there are now online pharmacist programs designed for flexibility and affordability. Graduates can pursue careers in clinical pharmacy, research, or industry settings.

Additionally, the growing field of healthcare data and records management is supported by online schools for health information management. These programs train students to manage and protect essential medical information, a critical role in modern healthcare systems.

Best Scientists Citing Raimund Jakesz

Trending Scientists

Recently Published Articles